Saw Palmetto
•Last Updated: August 18 2022
Saw Palmetto is a fatty acid mix from Serenoa repens that has been touted for its abilities to increase testosterone (not effective) and suppress prostate growth (questionable effectiveness); safe for use in benign prostatic hyperplasia and abnormal urine flow rates in men, but studies have had mixed results in terms of efficacy.
Saw Palmetto is most often used for
Last Updated: August 18 2022
Saw Palmetto is a supplement which is derived from the fruit of the plant Serenoa repens. The supplement (saw palmetto) has a caloric value, as it is rich in fatty acids.
Compounds in saw palmetto have the ability to block an enzyme that converts testosterone into dihydrotestosterone (DHT), the latter of which is more androgenic and can cause hair loss in the genetically susceptible. A couple of preliminary studies suggests supplementation with saw palmetto can promote hair regrowth, though more research is needed before strong conclusions can be made.
Saw Palmetto's effects on DHT production have also led to saw palmetto being used for benign prostatic hyperplasia (BPH) and lower urinary tract symptoms in men. Some studies have shown positive results, but larger and more well-designed studies have brought its efficacy into question.
Note that Saw Palmetto is also known as:
- Serenoa Repens
While the active compound(s) are not yet known, it is known that they exist in what is known as the "liposterolic" fraction of the fruits. If using saw palmetto, choose a product that discloses the percentage of the supplement which is this fraction.
Supplementation of saw palmetto tends to be in the range of 160-320 mg, taken once daily, of a product which is 80-90% liposterolic compounds by weight. While it is not confirmed if saw palmetto needs to be taken with food due to the fat soluble nature of this fraction, it is advised.
1.^Ernst EThe risk-benefit profile of commonly used herbal therapies: Ginkgo, St. John's Wort, Ginseng, Echinacea, Saw Palmetto, and KavaAnn Intern Med.(2002 Jan 1)
2.^De Monte C, Carradori S, Granese A, Di Pierro GB1, Leonardo C, De Nunzio CModern extraction techniques and their impact on the pharmacological profile of Serenoa repens extracts for the treatment of lower urinary tract symptomsBMC Urol.(2014 Aug 11)
3.^Schantz MM1, Bedner M, Long SE, Molloy JL, Murphy KE, Porter BJ, Putzbach K, Rimmer CA, Sander LC, Sharpless KE, Thomas JB, Wise SA, Wood LJ, Yen JH, Yarita T, NguyenPho A, Sorenson WR, Betz JMDevelopment of saw palmetto (Serenoa repens) fruit and extract standard reference materialsAnal Bioanal Chem.(2008 Oct)
4.^Weisser H1, Tunn S, Behnke B, Krieg MEffects of the sabal serrulata extract IDS 89 and its subfractions on 5 alpha-reductase activity in human benign prostatic hyperplasiaProstate.(1996 May)
5.^Abe M, Ito Y, Suzuki A, Onoue S, Noguchi H, Yamada SIsolation and pharmacological characterization of fatty acids from saw palmetto extractAnal Sci.(2009 Apr)
6.^Abe M, Ito Y, Oyunzul L, Oki-Fujino T, Yamada SPharmacologically relevant receptor binding characteristics and 5alpha-reductase inhibitory activity of free Fatty acids contained in saw palmetto extractBiol Pharm Bull.(2009 Apr)
7.^Habib FK1, Ross M, Ho CK, Lyons V, Chapman KSerenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expressionInt J Cancer.(2005 Mar 20)
8.^Goepel M1, Hecker U, Krege S, Rübben H, Michel MCSaw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitroProstate.(1999 Feb 15)
9.^Suzuki M1, Oki T, Sugiyama T, Umegaki K, Uchida S, Yamada SMuscarinic and alpha 1-adrenergic receptor binding characteristics of saw palmetto extract in rat lower urinary tractUrology.(2007 Jun)
10.^Takahashi D, Oyunzul L, Onoue S, Ito Y, Uchida S, Simsek R, Gunduz MG, Safak C, Yamada SStructure-activity relationships of receptor binding of 1,4-dihydropyridine derivativesBiol Pharm Bull.(2008 Mar)
11.^Suzuki M1, Ito Y, Fujino T, Abe M, Umegaki K, Onoue S, Noguchi H, Yamada SPharmacological effects of saw palmetto extract in the lower urinary tractActa Pharmacol Sin.(2009 Mar)
12.^Strauch G1, Perles P, Vergult G, Gabriel M, Gibelin B, Cummings S, Malbecq W, Malice MPComparison of finasteride (Proscar) and Serenoa repens (Permixon) in the inhibition of 5-alpha reductase in healthy male volunteersEur Urol.(1994)
13.^Albassam AA1, Mohamed ME, Frye RFInhibitory effect of six herbal extracts on CYP2C8 enzyme activity in human liver microsomesXenobiotica.(2014 Nov 28:1-7)
14.^Chittur S1, Parr B, Marcovici GInhibition of inflammatory gene expression in keratinocytes using a composition containing carnitine, thioctic Acid and saw palmetto extractEvid Based Complement Alternat Med.(2011)
15.^Latil A1, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen THexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitroBJU Int.(2012 Sep)
16.^Sirab N1, Robert G, Fasolo V, Descazeaud A, Vacherot F, Taille Ade L, Terry SLipidosterolic extract of serenoa repens modulates the expression of inflammation related-genes in benign prostatic hyperplasia epithelial and stromal cellsInt J Mol Sci.(2013 Jul 10)
17.^Iehlé C1, Délos S, Guirou O, Tate R, Raynaud JP, Martin PMHuman prostatic steroid 5 alpha-reductase isoforms--a comparative study of selective inhibitorsJ Steroid Biochem Mol Biol.(1995 Sep)
18.^Liang T1, Liao SInhibition of steroid 5 alpha-reductase by specific aliphatic unsaturated fatty acidsBiochem J.(1992 Jul 15)
19.^Bayne CW1, Donnelly F, Ross M, Habib FKSerenoa repens (Permixon): a 5alpha-reductase types I and II inhibitor-new evidence in a coculture model of BPHProstate.(1999 Sep 1)
20.^Délos S1, Carsol JL, Ghazarossian E, Raynaud JP, Martin PMTestosterone metabolism in primary cultures of human prostate epithelial cells and fibroblastsJ Steroid Biochem Mol Biol.(1995 Dec)
21.^Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, Descomps BInhibition of androgen metabolism and binding by a liposterolic extract of "Serenoa repens B" in human foreskin fibroblastsJ Steroid Biochem.(1984 Jan)
22.^Anderson ML1Evaluation of Resettin® on serum hormone levels in sedentary malesJ Int Soc Sports Nutr.(2014 Aug 23)
23.^Brown GA1, Vukovich MD, Reifenrath TA, Uhl NL, Parsons KA, Sharp RL, King DSEffects of anabolic precursors on serum testosterone concentrations and adaptations to resistance training in young menInt J Sport Nutr Exerc Metab.(2000 Sep)
24.^Brown GA1, Vukovich MD, Martini ER, Kohut ML, Franke WD, Jackson DA, King DSEndocrine and lipid responses to chronic androstenediol-herbal supplementation in 30 to 58 year old menJ Am Coll Nutr.(2001 Oct)
25.^Kohut ML1, Thompson JR, Campbell J, Brown GA, Vukovich MD, Jackson DA, King DSIngestion of a dietary supplement containing dehydroepiandrosterone (DHEA) and androstenedione has minimal effect on immune function in middle-aged menJ Am Coll Nutr.(2003 Oct)
26.^Brown GA1, Vukovich MD, Martini ER, Kohut ML, Franke WD, Jackson DA, King DSEffects of androstenedione-herbal supplementation on serum sex hormone concentrations in 30- to 59-year-old menInt J Vitam Nutr Res.(2001 Sep)
27.^Bertaccini A1, Giampaoli M, Cividini R, Gattoni GL, Sanseverino R, Realfonso T, Napodano G, Fandella A, Guidoni E, Prezioso D, Galasso R, Cicalese C, Scattoni V, Armenio A, Conti G, Corinti M, Spasciani R, Liguori G, Lampropoulou N, Martorana GObservational database serenoa repens (DOSSER): overview, analysis and results. A multicentric SIUrO (Italian Society of Oncological Urology) projectArch Ital Urol Androl.(2012 Sep)
28.^Jane EP1, Premkumar DR1, Morales A1, Foster KA1, Pollack IF2Inhibition of phosphatidylinositol 3-kinase/AKT signaling by NVP-BKM120 promotes ABT-737-induced toxicity in a caspase-dependent manner through mitochondrial dysfunction and DNA damage response in established and primary cultured glioblastoma cellsJ Pharmacol Exp Ther.(2014 Jul)
29.^Castellino RC1, Durden DLMechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumorsNat Clin Pract Neurol.(2007 Dec)
30.^Yang Y1, Hui L1, Yuqin C1, Jie L1, Shuai H1, Tiezhu Z1, Wei W1Effect of saw palmetto extract on PI3K cell signaling transduction in human gliomaExp Ther Med.(2014 Aug)
31.^Silvestri I1, Cattarino S2, Aglianò A1, Nicolazzo C1, Scarpa S3, Salciccia S2, Frati L4, Gentile V2, Sciarra A5Effect of Serenoa repens (Permixon®) on the expression of inflammation-related genes: analysis in primary cell cultures of human prostate carcinomaJ Inflamm (Lond).(2013 Mar 14)
32.^Marks LS1, DiPaola RS, Nelson P, Chen S, Heber D, Belldegrun AS, Lowe FC, Fan J, Leaders FE Jr, Pantuck AJ, Tyler VEPC-SPES: herbal formulation for prostate cancerUrology.(2002 Sep)
33.^Ng AC, Cheng KF, Leung PC1Prospective Trial of an Herbal Formula BYSH and Saw Palmetto in Patients with Hormonal Refractory Prostate Cancer: A Pilot StudyRecent Pat Inflamm Allergy Drug Discov.(2014)
34.^Bayne EK1, Flanagan J, Einstein M, Ayala J, Chang B, Azzolina B, Whiting DA, Mumford RA, Thiboutot D, Singer II, Harris GImmunohistochemical localization of types 1 and 2 5alpha-reductase in human scalpBr J Dermatol.(1999 Sep)
35.^Boersma IH, Oranje AP, Grimalt R, Iorizzo M, Piraccini BM, Verdonschot EH1The effectiveness of finasteride and dutasteride used for 3 years in women with androgenetic alopeciaIndian J Dermatol Venereol Leprol.(2014 Nov-Dec)
36.^Sato A1, Takeda AEvaluation of efficacy and safety of finasteride 1 mg in 3177 Japanese men with androgenetic alopeciaJ Dermatol.(2012 Jan)
37.^Gubelin Harcha W1, Barboza Martínez J2, Tsai TF3, Katsuoka K4, Kawashima M5, Tsuboi R6, Barnes A7, Ferron-Brady G8, Chetty D9A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopeciaJ Am Acad Dermatol.(2014 Mar)
38.^Olsen EA1, Hordinsky M, Whiting D, Stough D, Hobbs S, Ellis ML, Wilson T, Rittmaster RS; Dutasteride Alopecia Research TeamThe importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasterideJ Am Acad Dermatol.(2006 Dec)
39.^Prager N1, Bickett K, French N, Marcovici GA randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopeciaJ Altern Complement Med.(2002 Apr)
40.^Rossi A, Mari E, Scarno M, Garelli V, Maxia C, Scali E, Iorio A, Carlesimo MComparitive effectiveness of finasteride vs Serenoa repens in male androgenetic alopecia: a two-year studyInt J Immunopathol Pharmacol.(2012 Oct-Dec)
41.^Lepor H, Williford WO, Barry MJ, Brawer MK, Dixon CM, Gormley G, Haakenson C, Machi M, Narayan P, Padley RJThe efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study GroupN Engl J Med.(1996 Aug 22)
42.^Montgomery BT1, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF, Tindall DJHormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaPProstate.(1992)
43.^Wilt TJ, Ishani A, Rutks I, MacDonald RPhytotherapy for benign prostatic hyperplasiaPublic Health Nutr.(2000 Dec)
44.^Champault G, Patel JC, Bonnard AMA double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasiaBr J Clin Pharmacol.(1984 Sep)
45.^Ryu YW1, Lim SW, Kim JH, Ahn SH, Choi JDComparison of Tamsulosin Plus Serenoa Repens with Tamsulosin in the Treatment of Benign Prostatic Hyperplasia in Korean Men: 1-Year Randomized Open Label StudyUrol Int.(2015 Jan 23)
46.^Morgia G1, Russo GI, Voce S, Palmieri F, Gentile M, Giannantoni A, Blefari F, Carini M, Minervini A, Ginepri A, Salvia G, Vespasiani G, Santelli G, Cimino S, Allegro R, Collura Z, Fragalà E, Arnone S, Pareo RMSerenoa repens, lycopene and selenium versus tamsulosin for the treatment of LUTS/BPH. An Italian multicenter double-blinded randomized study between single or combination therapy (PROCOMB trial)Prostate.(2014 Nov)
47.^Tacklind J1, MacDonald R, Rutks I, Wilt TJSerenoa repens for benign prostatic hyperplasiaCochrane Database Syst Rev.(2009 Apr 15)
48.^Wilt T1, Ishani A, Mac Donald RSerenoa repens for benign prostatic hyperplasiaCochrane Database Syst Rev.(2002)
49.^Gerber GS1, Kuznetsov D, Johnson BC, Burstein JDRandomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptomsUrology.(2001 Dec)
50.^Bent S1, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins ALSaw palmetto for benign prostatic hyperplasiaN Engl J Med.(2006 Feb 9)
51.^Tacklind J, Macdonald R, Rutks I, Stanke JU, Wilt TJSerenoa repens for benign prostatic hyperplasiaCochrane Database Syst Rev.(2012 Dec 12)
52.^Miller LGHerbal medicinals: selected clinical considerations focusing on known or potential drug-herb interactionsArch Intern Med.(1998 Nov 9)
53.^Agbabiaka TB, Pittler MH, Wider B, Ernst ESerenoa repens (saw palmetto): a systematic review of adverse eventsDrug Saf.(2009)
55.^Wargo KA, Allman E, Ibrahim FA possible case of saw palmetto-induced pancreatitisSouth Med J.(2010 Jul)
56.^Lapi F, Gallo E, Giocaliere E, Vietri M, Baronti R, Pieraccini G, Tafi A, Menniti-Ippolito F, Mugelli A, Firenzuoli F, Vannacci AAcute liver damage due to Serenoa repens: a case reportBr J Clin Pharmacol.(2010 May)
57.^Miroddi M1, Carnì A, Mannucci C, Moleti M, Navarra M, Calapai GHot flashes in a young girl: a wake-up call concerning Serenoa repens use in childrenPediatrics.(2012 Nov)
58.^Morabito P, Miroddi M, Giovinazzo S, Spina E, Calapai GSerenoa repens as an Endocrine Disruptor in a 10-Year-Old Young Girl: A New Case ReportPharmacology.(2015)
Primary Use
Men’s Health